Abstract
Cancer immunotherapy is finally entering a new era with manipulation of cosignaling pathways as a therapeutic approach, for which the principle was proved nearly two decades ago. In addition to CTLA-4, CD137 and B7-H1/PD-1 pathways are two new targets in the stage. CD137 pathway is costimulatory and its agonistic antibody delivers potent signal to drive T cell growth and activation. On the other hand, blockade of B7-H1/PD-1 pathway with antagonistic antibody has shown to protect ongoing T cell responses from impairment by immune evasion mechanism in cancer microenvironment. With these tools in hand, a mechanism-based design of combined immunotherapy with high efficacy is becoming a reality.
| Original language | English (US) |
|---|---|
| Pages (from-to) | 245-267 |
| Number of pages | 23 |
| Journal | Current Topics in Microbiology and Immunology |
| Volume | 344 |
| Issue number | 1 |
| DOIs | |
| State | Published - 2010 |
ASJC Scopus subject areas
- Immunology and Allergy
- Microbiology (medical)
- Immunology
- Microbiology